Literature DB >> 20959400

Cancer epigenetics.

Rodolphe Taby1, Jean-Pierre J Issa.   

Abstract

Epigenetics refers to stable alterations in gene expression with no underlying modifications in the genetic sequence and is best exemplified by differentiation, in which multiple cell types diverge physiologically despite a common genetic code. Interest in this area of science has grown over the past decades, especially since it was found to play a major role in physiologic phenomena such as embryogenesis, imprinting, and X chromosome inactivation, and in disease states such as cancer. The latter had been previously thought of as a disease with an exclusive genetic etiology. However, recent data have demonstrated that the complexity of human carcinogenesis cannot be accounted for by genetic alterations alone, but also involves epigenetic changes in processes such as DNA methylation, histone modifications, and microRNA expression. In turn, these molecular alterations lead to permanent changes in the expression of genes that regulate the neoplastic phenotype, such as cellular growth and invasiveness. Targeting epigenetic modifiers has been referred to as epigenetic therapy. The success of this approach in hematopoietic malignancies validates the importance of epigenetic alterations in cancer, not only at the therapeutic level but also with regard to prevention, diagnosis, risk stratification, and prognosis.
© 2010 American Cancer Society, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959400     DOI: 10.3322/caac.20085

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  176 in total

Review 1.  DNA methylation in white blood cells: association with risk factors in epidemiologic studies.

Authors:  Mary Beth Terry; Lissette Delgado-Cruzata; Neomi Vin-Raviv; Hui Chen Wu; Regina M Santella
Journal:  Epigenetics       Date:  2011-07-01       Impact factor: 4.528

2.  Next-generation sequencing reveals regional differences of the α-synuclein methylation state independent of Lewy body disease.

Authors:  L de Boni; S Tierling; S Roeber; J Walter; A Giese; Hans A Kretzschmar
Journal:  Neuromolecular Med       Date:  2011-11-01       Impact factor: 3.843

Review 3.  Recent progress and clinical importance on pharmacogenetics in cancer therapy.

Authors:  Thomas I Peng Soh; Wei Peng Yong; Federico Innocenti
Journal:  Clin Chem Lab Med       Date:  2011-09-28       Impact factor: 3.694

4.  Discovery and activity profiling of thailandepsins A through F, potent histone deacetylase inhibitors, from Burkholderia thailandensis E264.

Authors:  Cheng Wang; Creston J Flemming; Yi-Qiang Cheng
Journal:  Medchemcomm       Date:  2012-08-01       Impact factor: 3.597

Review 5.  Cancer epigenetics: above and beyond.

Authors:  Mariana Brait; David Sidransky
Journal:  Toxicol Mech Methods       Date:  2011-05       Impact factor: 2.987

6.  The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas.

Authors:  Luka de Vos; Ingela Grünwald; Emma Grace Bawden; Jörn Dietrich; Kathrin Scheckenbach; Constanze Wiek; Romina Zarbl; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  Epigenetics       Date:  2020-04-21       Impact factor: 4.528

7.  Targeting and eradicating hepatic cancer cells with a cancer-specific vector carrying the Buforin II gene.

Authors:  Yanyun Wang; Lili Qu; Lailing Gong; Li Sun; Rujun Gong; Jin Si
Journal:  Cancer Biother Radiopharm       Date:  2013-06-25       Impact factor: 3.099

8.  Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.

Authors:  Hanghang Zhang; Somnath Pandey; Meghan Travers; Hongxing Sun; George Morton; Jozef Madzo; Woonbok Chung; Jittasak Khowsathit; Oscar Perez-Leal; Carlos A Barrero; Carmen Merali; Yasuyuki Okamoto; Takahiro Sato; Joshua Pan; Judit Garriga; Natarajan V Bhanu; Johayra Simithy; Bela Patel; Jian Huang; Noël J-M Raynal; Benjamin A Garcia; Marlene A Jacobson; Cigall Kadoch; Salim Merali; Yi Zhang; Wayne Childers; Magid Abou-Gharbia; John Karanicolas; Stephen B Baylin; Cynthia A Zahnow; Jaroslav Jelinek; Xavier Graña; Jean-Pierre J Issa
Journal:  Cell       Date:  2018-10-25       Impact factor: 41.582

9.  DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus.

Authors:  Muhammad A Alvi; Xinxue Liu; Maria O'Donovan; Richard Newton; Lorenz Wernisch; Nicholas B Shannon; Kareem Shariff; Massimiliano di Pietro; Jacques J G H M Bergman; Krish Ragunath; Rebecca C Fitzgerald
Journal:  Clin Cancer Res       Date:  2012-12-14       Impact factor: 12.531

10.  The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis.

Authors:  Jie Yang; Wen Gao; Ning-Hong Song; Wei Wang; Jie-Xiu Zhang; Pei Lu; Li-Xin Hua; Min Gu
Journal:  Asian J Androl       Date:  2012-08-20       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.